Third Rock Ventures launches new biotech, SAGE Therapeutics
Bizjournals.com
Proximagen polishes its CNS rep with $16M Lundbeck deal
Fierce Biotech
Submitted by gmonari on Mon, 08/22/2011 - 12:28
AMRI Receives NIH Contract Award for the Development of Preclinical Drug Candidates to Treat Diseases of the Nervous System
Albany, NY (August 18, 2011) – AMRI (NASDAQ: AMRI) today announced it received a federal contract
award from the National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS) to provide chemistry and other drug discovery technologies in support of NINDS’ Medicinal Chemistry for Neurotherapeutics Program (MCNP), part of the NIH Blueprint Neurotherapeutics Network. AMRI has been collaborating with NINDS since 2005 on novel treatments for spinal muscular atrophy, a degenerative neuromuscular disease.
News
PipeLine Review